Epidemiology: The dominant malignancy

  title={Epidemiology: The dominant malignancy},
  author={Eric Bender},
  • E. Bender
  • Published 11 September 2014
  • Medicine
  • Nature
Lung cancer is the leading cause of cancer mortality. In some countries, incidence rates are dropping but survival rates for those with the disease remain low. By Eric Bender. 
Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases
There is an urgent need to understand the mechanisms of cancer progression in LUAD and to identify useful biomarkers to predict prognosis.
Identification of differential protein‐coding gene expressions in early phase lung adenocarcinoma
This study aimed to identify protein‐coding genes that can be used as biomarkers of early stage LADC.
Non-invasive approaches for lung cancer diagnosis
Novel non-invasive lung cancer diagnostic strategies could improve and complement the success of CT-scan and chest X-ray and provide critical information regarding tumor growth pattern, cells of origin of tumor, subtype of lung cancer, and/or drug metabolism as well as monitor patient prognosis.
Construction of a Prognostic Model in Lung Adenocarcinoma Based on Ferroptosis-Related Genes
A ferroptosis-related gene-based prognostic model verified the prognostic significance of FRGs in patients with lung adenocarcinoma, which may regulate tumor progression in a variety of pathways.
Non-small-cell lung cancer
This Primer focuses on non-small-cell lung cancer, a heterogeneous class of tumours, which represents approximately 85% of all new lung cancer diagnoses and has a very poor prognosis.
An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer
  • Chitra Thakur
  • Medicine
    Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer
  • 2019
Basic molecular alterations in NSCLC are discussed, which will aid in the identification of new targets, defining novel molecular biomarkers and how they can be exploited to improve the current state of early cancer detection and overcome drug resistance.
Chinese consensus on early diagnosis of primary lung cancer (2014 version)
A diagnostic strategy for lung cancer should be proposed and developed by a multidisciplinary group and a comprehensive evaluation of patient factors and clinical findings should be completed before treatment.
A nomogram to predict overall survival of patients with early stage non-small cell lung cancer.
A nomogram incorporating available clinicopathological variables to predict overall survival of early stage NSCLC patients after surgery resection is successfully developed, which might help clinician select better appropriate treatment decisions.
Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China
The EGFR mutations in lung adenocarcinoma patients were independently correlated with distant metastases and subgroup analyses showed that patients harboring 19del mutations presented different distant metastase compared with those harboring 21 point mutaions.
The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non–Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy123
MUC5B promoter polymorphism could be prognostic of the OS among NSCLC patients receiving definitive radiotherapy, although no significant associations were found with the risk of RP.


Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact.
The recommended annual low dose computed tomography treatment for lung cancer screening should be switched to once a year, based on evidence from the National Lung Cancer Screening Trial (NLST).
Targeting the affordability of cigarettes: a new benchmark for taxation policy in low-income and-middle-income countries
It is shown that a tax incidence benchmark is not an optimal policy tool in South Africa and that an affordability benchmark could be a more effective means of reducing tobacco consumption in the future.